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DMARD treatment during the first 2 years of
rheumatoid arthritis: experience in the ERAN
inception cohort
Daniel F McWilliams1*, Patrick D W Kiely2, Adam Young3 and David A Walsh1,4Abstract
Background: Outcomes in early Rheumatoid Arthritis (RA) may be improved by rapidly establishing a stable and
effective disease modifying anti-rheumatic drug (DMARD) treatment regimen. We aimed to investigate whether
baseline factors and initial treatment strategies are associated with changes to the first DMARD treatment, due to
either Lack of Efficacy (LoE) or Adverse Drug Reaction (ADR) within 2 years of presentation.
Methods: Reasons for changes from initial DMARD therapy within 2 years of baseline, and associated factors, were
examined using logistic regression in data from the Early RA Network (ERAN) inception cohort.
Results: Data were available for 766 participants. 410 (54%) changed their initial DMARD regime within 2 years,
including 230 (56%) due to Lack of Efficacy (LoE) and 139 (34%) due to Adverse Drug Reaction (ADR). The first
DMARD was recorded as methotrexate monotherapy in 336 (44%), sulphasalazine monotherapy in 273 (36%), or
combined methotrexate/sulphasalazine/hydroxychlorquine in 52 (7%).
Baseline predictors of changing DMARD (for all reasons) were HAQ-disability (aOR 1.44, 95% CI 1.12 – 1.86), poor
mental health (aOR 1.44, 95% CI 1.16 – 1.78) and extra-articular disease (aOR 1.78, 95% CI 1.00 – 3.16). In this model,
the triple combination therapy also predicted lower likelihood of DMARD change (aOR 0.30, 95% CI 0.12 – 0.79).
Subgroup analyses showed that MTX monotherapy was associated with lower risk of change due to ADR.
Combination therapy conferred lower risk of change due to LoE. Poor mental health was associated with change
due to ADR, and extra-articular disease, HAQ-disability at baseline, and younger age predicted LoE.
Conclusions: Our findings suggest that non-pharmacological interventions to improve disability and mental health,
may reduce initial DMARD treatment failure.
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In early RA, the introduction of an effective initial therapy
and rapid control of inflammatory disease activity can im-
prove both short and long term outcomes [1-3]. Combi-
nation disease modifying anti-rheumatic drug (DMARD)
therapies are recommended for initial treatment of se-
verely active rheumatoid arthritis, although many patients
continue to be treated with monotherapies [4-6]. Failure* Correspondence: dan.mcwilliams@nottingham.ac.uk
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distribution, and reproduction in any mediumof the initial treatment, often due to inadequate benefit or
adverse events, can delay treatment optimisation and dis-
ease stabilisation.
Methotrexate (MTX) is often considered the most effi-
cacious of traditional DMARD monotherapies and may
be discontinued less often than other DMARDs [2]. In
studies of established RA, average durations for which
MTX treatment was maintained ranged between 19
and >96 months [1,7-10]. Studies of discontinuation in
early RA support these findings from established disease.
Within 2 years of treatment initiation, MTX monotherapy
was discontinued in 15%, compared to sulphasalazinetral Ltd. This is an Open Access article distributed under the terms of the
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continued on average for 60 months, compared to
21 months for SSZ [12]. MTX may be discontinued less
often than other DMARDs even if previous treatments
have failed [13].
Reported risk factors for the discontinuation of
DMARDs are increasing age or pre-treatment anxiety at
baseline [11,14], shorter disease duration, or previous
failure of DMARDs [12]. Disease activity may be associ-
ated with initial DMARD choice, but is not necessarily
associated with discontinuation [8]. It is unclear, how-
ever, whether these or other factors are the main predic-
tors of DMARD discontinuation in early RA, or whether
different factors predict discontinuation either due to
lack of efficacy or to adverse events [11]. Better un-
derstanding factors that may contribute to disconti-
nuation of first DMARD could aid clinicians to more
rapidly establish people with early RA on their definitive
treatment.
The Early Rheumatoid Arthritis Network (ERAN) is
an inception cohort of people with newly diagnosed RA
which commenced in 2002. We aimed to identify clinical
and quality of life measures associated with early DMARD
discontinuation, and discontinuation due to ADR or LoE,
within 2 years of the first diagnosis.
Methods
Patients and recruitment
The ERAN inception cohort study, recruits from 22 out-
patient centres in the UK and Eire [15]. Recruitment
began in April 2002. By the end of July 2009, 1133
patients had enrolled in the study. Participants are re-
cruited following the first diagnosis of RA by a rheu-
matologist and clinical data collected at baseline, 3 to
6 months, and annually from baseline thereafter. People
whose diagnosis was subsequently changed were with-
drawn and removed from the study database. ERAN
centres treat patients according to local practice. The
study was approved by Trent Research Ethics Commit-
tee (ref 01/4/047) and all participants gave signed, in-
formed consent in line with the Declaration of Helsinki.
Data collection
Data collected at baseline and drug data up to the 2 year
follow up (visit number 4, median time = 24 months)
were used for this study. At baseline clinicians re-
corded extra-articular disease manifestations [16] or
co-morbidities [17] as previously described. Participants
reported the duration of their symptoms and completed
Short Form 36 (SF36) [18] and Health Assessment (HAQ)
[19] questionnaires. SF36 subscales were not “normed” for
age or gender (as both would be adjusted for during ana-
lyses). Erythrocyte sedimentation rate (ESR) was obtained
from the clinical record. Rheumatoid factor (RF) and/orcyclic citrullinated proteins (CCP) were pooled to give
either seropositive (RF positive and/or CCP positive) or
seronegative (negative or weakly positive for RF and nega-
tive for CCP) classifications. The DAS28-ESR score was
used as the measure of disease activity [20], and the
DAS28-P score was calculated as the proportion of disease
activity score contributed by patient-reported factors (ten-
der joint count and general health visual analogue scale)
[21]. Whether 4 or more of the 1987 ACR RA classifica-
tion criteria were satisfied at baseline was derived from
the ERAN database [22]. Baseline radiographs of hands
and feet were examined by staff at the collecting ERAN
centre and classified as having one or more erosions or no
erosions.
Change of initial DMARD treatment
Data were analysed from participants who had been re-
cruited prior to July 2009, ≥ 2 years before data retrieval
for this analysis, and who had commenced DMARD be-
fore visit 4. The reason for stopping or changing DMARD
was recorded by each study centre as “adverse drug
reaction” (ADR), “lack of efficacy” (LoE), “ADR and
LoE”, “surgery”, “patient choice”, “non-compliance”,
“other” or “unknown”. “Change” was defined as stop-
ping all DMARD therapy for at least 2 months, alter-
ing the existing DMARD therapy (including addition
of DMARDs to introduce combination therapy) or swit-
ching DMARD regimes (with one beginning < 3 months
from the other finishing). Introduction of biologic therap-
ies were recorded as changes, but alteration of DMARD
dosages or route of administration were not examined in
these analyses. When no reason was recorded for the
addition of new DMARD therapy, it was assumed that this
was due to lack of efficacy, and these patients were added
to the LoE group (similarly to other reports [7]). In those
patients for whom follow up data were missing between
baseline and visit 4 or alteration of DMARD regime, a ver-
sion of the “last observation brought forward” approach
was used where those that did not change (n = 331) were
excluded, and those that changed before visit 4 were
included (n = 128). Those who were not prescribed
DMARDs before study visit 4 (n = 8) or who had incom-
plete data records (n = 28) were excluded from analysis.
Statistical analysis
Univariate data analyses were performed using Mann–
Whitney U-tests and χ2 tests for categorical data, not
corrected for multiple comparisons. For analysis pur-
poses baseline DAS28 scores were classified into EULAR
activity groups (0–3.19, 3.2-5.19, ≥5.2 [23]) (only 53
people were in DAS28 remission (<2.6) at baseline, and
therefore remission and low disease activity subgroups
were combined for analysis); BMI was classified into
WHO groups (<25; 25–29.9; ≥30 [24]); and other
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creasing severity/magnitude. The highest quartile was al-
ways the most severe or least beneficial (eg. high pain, low
mental health, high HAQ score etc.) and the least severe
was used as the reference. Logistic regression was used to
examine independent associations between baseline fac-
tors and changing of DMARDs within 2 years, followed
by risks for changing due to LoE and ADR. Categorical
dummy variables for initial DMARDs were limited to
MTX monotherapy, SSZ monotherapy and triple therapy
due to clinical relevance and low usage of other therapies.
Logistic regression was performed to investigate inde-
pendent risk factors for DMARD change. Age, gender,
DAS28 and baseline DMARD regimen were all included
in each model, as key descriptive clinical variables. Other
variables were selected if associated with DMARD change
at the univariate level for one of the analyses. The same
variables were included in each logistic regression model
for each outcome. Sensitivity analyses were also performed
using different definitions of combination therapy, smo-
king history and diagnostic criteria. Statistical significance
was taken when p < 0.05.
Results
A total of 766 people had data available for analysis. Rea-
sons for inclusion/exclusion are summarised in Figure 1.
Age and gender prevalence were similar for included
and excluded cases, but those included in the analysesFigure 1 Selection of participants for analysis.had, at baseline, slightly higher DAS28 scores (median
(IQR) 5.8 (4.6 – 7.0) vs 5.5 (4.1 – 6.7)) and slightly grea-
ter HAQ-disability (median (IQR) 1.1 (0.6 – 1.8) vs 0.9
(0.4 – 1.5)).
Of the 766 participants, 54% (n = 410) changed their
initial DMARD regime between baseline and study visit
4. This group was comprised of those where an add-
itional DMARD had been added (n = 182), those that
switched to a new DMARD (n = 134) and those where
DMARD treatment ceased for at least 2 months (n = 94).
The commonest reasons for changing a DMARD were
ADR (139 (34%)) and LoE (230 (56%)). “Other” was re-
corded for 22 patients and other codes were assigned to
the remaining 19 patients (including the code for LoE &
ADR combined). The comparator group (n = 356) had
not changed their initial DMARD by study visit 4 (me-
dian time from baseline to study visit 4 was 24 months).
The initial DMARD treatments are listed in Table 1
and the patient demographics are shown in Table 2. Par-
ticipants given initial SSZ monotherapy had slightly bet-
ter median (IQR) DAS28 (4.7 (3.7 – 5.7)) and were less
likely to be seropositive (52%) than those initially treated
with MTX monotherapy (DAS28: 5.1 (4.1 – 6.1) and
66% seropositive; each p < 0.05). Otherwise, the demo-
graphics of three commonest treatment groups were sta-
tistically similar.
Table 2 shows the univariate analyses of baseline factors
compared between groups. Univariate analysis found that
the recorded reasons for changing DMARDs differed be-
tween groups (change for any reason χ2 = 31.2, p < 0.001;
LoE χ2 = 10.7, p = 0.014, ADR χ2 = 63.9, p <0.001). Chan-
ging DMARD was associated with gender, previous smo-
king, HAQ disability, 1987 ACR criteria, extra-articular
disease, DAS28, DAS28-P, Bodily Pain and Mental Health
scores. There were 111/336 (33%) patients reported as
changing from MTX monotherapy due to LoE and 27/336Table 1 Initial DMARD regimens
Initial DMARD regimen






Combination therapies (n = 96)
MTX + SSZ + HCQ 6.8%
MTX + SSZ 2.7%
MTX + HCQ 1.4%
Others 1.6%
Prevalences of intial DMARD treatments in ERAN participants stratified into
monotherapies and combination therapies. MTX methotrexate, SSZ
suplphasalazine, HCQ hydroxychloroquine, Lef leflunomide.
Table 2 Characteristics of patient study groups
No change
of DMARD
Change of DMARD Reason for change
Adverse drug reaction Lack of efficacy
N 356 410 139 230
Female 65% 72% * 71% 72%
Age (yrs) 58 (47–68) 56 (46–66) 60 (50–70) 54 (44–63) **
BMI (kg/m2) 26.4 (23.9 - 30.1) 26.9 (23.7 - 30.8) 26.6 (23.8 - 30.5) 27.2 (23.9 - 31.2)
Ever smoked 57% 65% * 66% 65%
Current smoker 35% 39% 39% 37%
Symptom duration (mo) 6 (4–12) 6 (4–12) 5 (3–10) 6 (3–13)
Erosions 47% 26% 23% 28%
HAQ (0–3) 1.0 (0.4 - 0.6) 1.4 (0.8 - 1.9) ** 1.3 (0.6 - 1.8) * 1.4 (0.8 - 1.9) **
>4 of 1987 ACR criteria 51% 59% * 53% 65% **
Seropositive 62% 61% 54% 64%
Extra-articular disease 11% 20% ** 15% 24% **
Co-morbidity 44% 50% 56% * 49%
DAS28 4.6 (3.6 - 5.7) 5.1 (4.0 - 6.1) ** 4.8 (3.5 - 5.7) 5.4 (4.1 - 6.2) **
DAS28-P (0–1) 0.41 (0.32 - 0.47) 0.43 (0.35 - 0.50) ** 0.42 (0.32 - 0.50) 0.43 (0.37 - 0.50) **
SF36-Bodily pain (0–100) 41 (31–62) 32 (22–51) ** 41 (22–62) * 31 (21–42) **
SF36-Mental Health (0–100) 68 (52–80) 60 (48–72) ** 60 (48–72) ** 56 (48–70) **
Steroid at baseline 17% 16% 14% 16%
Sulphasalazine monotherapy 27% 43% 59% 33%
Methotrexate monotherapy 53% 36% 23% 48%
Other monotherapy 4% 11% 9% 12%
Dual therapy 6% 5% 7% 4%
Triple therapy 10% 4% 2% 4%
Comparison of patient groups based upon DMARD changes. Medians (IQR) or percentage prevalences are presented. ** p < 0.01, * p < 0.05 for comparison vs No
Change. Statistically significant results are presented in bold (with the exception of DMARD treatments, which were also significantly heterogeneous, but tested as
a group).
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273 (28%) changed due to LoE and 85/273 (31%) due to
ADR. One hundred and twenty two people (16%) were re-
ceiving steroids at baseline, but this was not significantly
associated with the future change of DMARD treatment
(Table 2). Neither MTX monotherapy, SSZ monotherapy
nor triple therapy were more likely to be associated with
baseline steroid usage (data not shown). In those that
changed their initial DMARD treatment, the median
(IQR) times until change were 6 (3 – 11) months for SSZ,
9 (6 – 16) months for MTX and 17 (8 – 24) for triple
therapy.
Logistic regression was used to examine baseline fac-
tors associated with subsequent change of DMARD for
any reason, including both LoE and ADR (Table 3). In-
creasing HAQ-disability (aOR 1.44 (95% CI 1.12 - 1.86,
p = 0.005); extra-articular disease (aOR 1.78, 95% CI
1.00 – 3.16, p = 0.050); and worse SF36-Mental Health
subscale scores (aOR 1.44, 95% CI 1.16 – 1.78, p < 0.001)
were each associated with change of DMARD. Tripletherapy as first treatment was associated with less risk of
subsequent DMARD change (aOR 0.30, 95% CI 0.12 –
0.79, p = 0.014). Head to head comparative analysis
between MTX monotherapy and SSZ monotherapy
favoured MTX as initial DMARD (aOR 0.41, 95% CI
0.28 – 0.60, p < 0.001). Sensitivity analyses showed that
exchanging previous smokers for current smokers did
not alter the main findings, and did not yield a statisti-
cally significant association between smoking and
DMARD change. Findings also were unchanged by only
including people that commenced DMARD therapy
within 12 months from baseline, instead of including all
people who commenced DMARDs before visit 4 (data
not shown). Furthermore, sensitivity analyses only in-
cluding participants who satisfied ACR 1987 classifica-
tion criteria for RA did not affect statistical associations
between baseline factors and DMARD change (data not
shown).
Analyses of subgroups were performed for change due
to LoE or ADR. Logistic regression models showed that
Table 3 Logistic regression models of non-persistence of DMARD
Variable Categories Risk of change Reasons for changing DMARD
Risk of adverse drug reaction Risk of lack of efficacy
Female gender Y/N 1.11 (0.69 - 1.80) 1.52 (0.81 – 2.85) 1.20 (0.71 – 2.03)
Age Quartiles 0.89 (0.72 - 1.10) 1.23 (0.94 – 1.60) 0.69 (0.55 – 0.87) **
Ever smoked Y/N 1.38 (0.89 - 2.15) 1.29 (0.59 – 2.78) 1.35 (0.83 – 2.19)
DAS28 EULAR categories 1.12 (0.78 - 1.62) 0.95 (0.58 – 1.57) 1.29 (0.83 – 2.02)
>4 of 1987 ACR criteria Y/N 0.98 (0.59 – 1.65) 1.04 (0.57 – 1.91) 1.20 (0.72 – 2.01)
Extra-articular disease Y/N 1.78 (1.00 - 3.16) * 1.29 (0.59 – 2.78) 2.27 (1.25 – 4.11) **
Co-morbidities Y/N 1.02 (0.66 - 1.57) 1.18 (0.67 – 2.09) 0.82 (0.51 – 1.32)
HAQ score Quartiles 1.44 (1.12 - 1.86) ** 1.10 (0.80 – 1.52) 1.36 (1.03 – 1.81) *
SF36-bodily pain Quartiles 0.93 (0.72 - 1.19) 1.03 (0.75 – 1.43) 1.18 (0.90 – 1.55)
SF36-mental health Quartiles 1.44 (1.16 - 1.78) ** 1.43 (1.08 – 1.89) * 1.22 (0.97 – 1.52)
DAS28-P Quartiles 1.09 (0.88 - 1.35) 1.04 (0.79 – 1.37) 1.10 (0.86 – 1.41)
SSZ monotherapy Y/N 1.09 (0.57 - 2.12) 1.92 (0.85 – 4.37) 0.74 (0.35 – 1.54)
MTX monotherapy Y/N 0.56 (0.29 - 1.06) 0.38 (0.16 – 0.94) * 0.57 (0.28 – 1.17)
MTX + SSZ + HCQ Y/N 0.30 (0.12 - 0.79) * 0.33 (0.08 – 1.38) 0.14 (0.04 – 0.53) **
Variables associated with a non-persistence of DMARD treatment within the first 2 years in the ERAN cohort (428 people had data analysed). Adjusted odds ratios
(95% confidence intervals). * = p < 0.05, ** = p < 0.01. Statistically significant results are presented in bold.
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articular disease and with HAQ-disability, and negatively
associated with age and triple therapy as initial DMARD
regime. ADR was associated with worse SF36-Mental
Health subscale scores and negatively with MTX mono-
therapy (Table 2).
In further sensitivity analyses, substituting all MTX-
containing combinations instead of MTX + SSZ +HCQ
triple therapy did not affect the significant findings. For
example, in logistic regression for DMARD change for
all reasons, the statistically significant aOR (95% CI)
were Mental Health score 1.32 (1.08 – 1.60), p = 0.006;
extra-articular disease 1.81 (1.06 – 3.07), p = 0.028; HAQ
1.32 (1.05 – 1.67), p = 0.020; MTX monotherapy 0.25
(0.12 – 0.54), p < 0.001; MTX-combination 0.17 (0.07 –
0.43), p < 0.001).
Discussion
In this study we found that changing from the first pre-
scribed DMARD within 2 years of presentation was pre-
dicted by the baseline higher levels of HAQ-disability,
worse mental health and presence of extra-articular
disease. Also, the choice of first DMARD was associ-
ated with the risk of subsequent change, with patients
most likely to persist with MTX (consistent with a pre-
vious report [12]) and triple therapy of MTX + SSZ +
hydroxychloroquine.
We and others have shown previously that choice of
SSZ or MTX as initial DMARD in patients with early
rheumatoid arthritis was associated with classical prog-
nostic factors and disease activity, particularly rheuma-
toid factor seropositivity and swollen joint counts [6,25].Extra-articular disease at baseline, another poor prog-
nostic factor, was associated with DMARD changes due
to LoE, and others have found that extra-articular dis-
ease may predict adverse events on DMARDs [26].
Contemporaneous disease activity influenced decisions
to change from the initial DMARD, as indicated by the
large proportion of patients whose change was attributed
to LoE. However, LoE during the first 2 years was not
predicted by baseline disease activity, and we found that
factors other than inflammatory disease prognosis were
important predictors of DMARD change. The effects
of mental health and disability in predicting DMARD
change were independent of RA inflammatory disease
severity as measured by DAS28, which was adjusted for
in the logistic regression analyses. Pain at baseline sig-
nificantly predicted DMARD change at the univariate
level, although significance was lost after adjustments
for other factors. These findings suggest that in contem-
porary practice which focuses on suppression of inflam-
matory disease activity, other symptoms such as poorer
mental health or higher HAQ-disability at baseline may
affect DMARD discontinuation decisions in the clinic,
regardless of the measurable disease activity or reported
pain.
We found that poorer mental health scores at baseline
predicted subsequent change in DMARD regimen, espe-
cially for ADR. Listing et al., 1997 reported that poor
mental health was associated with subsequent DMARD
discontinuation in people with early RA [11], and people
with higher levels of anxiety were more likely to discon-
tinue initial DMARD [14]. Poor mental health may be
associated with non-inflammatory pain mechanisms in
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fill fibromyalgia classification criteria [27]. Influence of
mental health status and non-inflammatory pain me-
chanisms on DMARD discontinuation deserves further
study. Psychological and medical interventions have po-
tential to improve mental health, and therefore facilitate
continuation with DMARD regimens, especially if poo-
rer mental health is associated with poorer treatment ad-
herence. The prediction of DMARD changes by baseline
disability indicates that initial DMARD monotherapy
may deal inadequately with disability. Further studies
would be required to determine whether addressing dis-
ability itself may facilitate DMARD continuation.
As expected, the original DMARD choice also pre-
dicted changes to DMARDs during the first 2 years. Use
of MTX alone or as a part of combination therapy was
associated with lower risk of DMARD change, either
due to LoE or ADR. Current UK guidelines recommend
that the initial treatment of active RA should include
MTX [28]. Our data indicate that the greater likelihood
that regimens containing MTX will be continued [7,29]
is independent of baseline disease activity. This suggests
that MTX should not be withheld from patients with
low or moderate disease activity at baseline.
We were unable to confirm previous findings that
older patients were more likely to discontinue DMARDs
[14]. Indeed, older participants were less likely to change
DMARD due to LoE, possibly indicating a greater ac-
ceptance of disease activity by patients or their physi-
cians. Consistently with this, older patients in ERAN
were less likely to be prescribed DMARDs. However,
further research is required to determine whether differ-
ent treatment strategies should be adopted in elderly
patients.
There are several limitations to this analysis. We used
DAS-ESR a validated measure of inflammatory disease
activity in common clinical use. However, DAS-ESR may
be affected by factors other than disease activity [21] and
further work would be required to determine whether
other baseline measures of disease activity, for example
incorporating C-reactive protein rather than ESR, may
predict subsequent DMARD changes. DMARDs were
sometimes changed without the reason being formally
recorded, although it is likely that addition of a new
DMARD whilst continuing the initial DMARD repre-
sents lack of adequate efficacy of the initial monotherapy
[7]. Also, the clinical decision-making process is com-
plex, taking account of patient and physician prefer-
ences, changing local guidance as well as LoE and ADR.
Our subgroups may represent heterogeneous reasons for
DMARD change that could not be fully elucidated. Not
all DMARD treatments could be modelled without over-
adjusting the results. The two commonest monother-
apies and triple DMARD therapy were included as beingmost-relevant to clinical practice, and further research
may determine whether similar factors predict discon-
tinuation of other initial DMARD regimens.
Conclusions
This is a large study of DMARD change in early RA.
Changing within 2 years from initial DMARD therapy
was predicted by baseline disability, poorer mental health
and the presence of extra-articular disease. Early initiation
of intensive treatment, including MTX at baseline, and
non-pharmacological measures to improve disability and
mental health may have potential to reduce morbidity and
cost from initial treatment failure.
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